These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 9074562)

  • 21. [Fluoroquinolones: pharmacology, antibacterial spectrum and indications in pneumology].
    Underner M; Grignon B; Roblot F; Meurice JC; Patte F
    Rev Pneumol Clin; 1989; 45(1):14-22. PubMed ID: 2662344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibiotics in primary care: focus on fluoroquinolones and other new and investigational antimicrobial agents.
    Pau AK; Slone RB
    Lippincotts Prim Care Pract; 1999; 3(1):39-54. PubMed ID: 10214201
    [No Abstract]   [Full Text] [Related]  

  • 23. In vitro antimicrobial activity of fluoroquinolones against clinical isolates obtained in 1989 and 1990.
    Chen YC; Chang SC; Hsu LY; Hsieh WC; Luh KT
    J Formos Med Assoc; 1993 Dec; 92(12):1040-8. PubMed ID: 7911351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluoroquinolone resistance in staphylococci: new challenges.
    Sanders CC; Sanders WE; Thomson KS
    Eur J Clin Microbiol Infect Dis; 1995; 14 Suppl 1():S6-11. PubMed ID: 7729471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fluoroquinolones and risk for methicillin-resistant Staphylococcus aureus, Canada.
    LeBlanc L; Pépin J; Toulouse K; Ouellette MF; Coulombe MA; Corriveau MP; Alary ME
    Emerg Infect Dis; 2006 Sep; 12(9):1398-405. PubMed ID: 17073089
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Impact of fluoroquinolone use on multidrug-resistant bacteria emergence].
    Nseir S; Ader F; Marquette CH; Durocher A
    Pathol Biol (Paris); 2005; 53(8-9):470-5. PubMed ID: 16176863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of fluoroquinolones against gram-positive bacteria.
    Bush K; Goldschmidt R
    Curr Opin Investig Drugs; 2000 Sep; 1(1):22-30. PubMed ID: 11249591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dichotomous selection of high-level oxacillin resistance in Staphylococcus aureus by fluoroquinolones.
    Dalhoff A; Schubert S
    Int J Antimicrob Agents; 2010 Sep; 36(3):216-21. PubMed ID: 20630710
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.
    Entenza JM; Que YA; Vouillamoz J; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3076-83. PubMed ID: 11600359
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antimicrobial photodynamic inactivation and photodynamic therapy for infections.
    Huang L; Dai T; Hamblin MR
    Methods Mol Biol; 2010; 635():155-73. PubMed ID: 20552347
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia.
    Drusano GL; Preston SL; Fowler C; Corrado M; Weisinger B; Kahn J
    J Infect Dis; 2004 May; 189(9):1590-7. PubMed ID: 15116294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibiotic resistance-the problem intensifies.
    Levy SB
    Adv Drug Deliv Rev; 2005 Jul; 57(10):1446-50. PubMed ID: 15949867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis.
    Marangon FB; Miller D; Muallem MS; Romano AC; Alfonso EC
    Am J Ophthalmol; 2004 Mar; 137(3):453-8. PubMed ID: 15013867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Does the emergence of antibiotic resistance announce the return of the dark ages?].
    Elhani D
    Ann Biol Clin (Paris); 2011; 69(6):637-46. PubMed ID: 22123562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Update on the treatment of diabetic foot infections.
    Kosinski MA; Joseph WS
    Clin Podiatr Med Surg; 2007 Jul; 24(3):383-96, vii. PubMed ID: 17613382
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [From Pneumococcus to Pseudomonas: the antibacterial behaviour through the time].
    Rossolini GM
    Infez Med; 2009 Dec; 17 Suppl 5():5-12. PubMed ID: 20424531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aminoglycoside resistant enterococcal endocarditis.
    Eliopoulos GM
    Infect Dis Clin North Am; 1993 Mar; 7(1):117-33. PubMed ID: 8463648
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fluoroquinolone resistance: mechanisms and epidemiology.
    Tillotson GS; Dorrian I; Blondeau J
    J Med Microbiol; 1997 Jun; 46(6):457-61. PubMed ID: 9379475
    [No Abstract]   [Full Text] [Related]  

  • 39. Pseudomonas aeruginosa, Staphylococcus aureus, and fluoroquinolone use.
    MacDougall C; Harpe SE; Powell JP; Johnson CK; Edmond MB; Polk RE
    Emerg Infect Dis; 2005 Aug; 11(8):1197-204. PubMed ID: 16102307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pseudomonas aeruginosa corneal abscess refractory to fluoroquinolones].
    Díaz Valle D; Alós Cortés JI; Arteaga Sánchez A; Toledano Fernández N; Poza Morales Y; Díaz-Valle T
    Arch Soc Esp Oftalmol; 2002 Jul; 77(7):397-9. PubMed ID: 12098814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.